With infections caused by the fungal pathogen Candida auris spreading at an “alarming ... has just picked up a timely FDA approval for its antifungal drug Rezzayo. Melinta – which has US ...

Particular attention is paid to new challenges such as resistance to common antifungals and the increasing spread of Candida auris, a multi-resistant pathogen. "With this guideline, we have taken ...

Candida auris, a drug-resistant fungal pathogen, poses a significant threat to healthcare settings, particularly in the New York-New Jersey area, which accounts for nearly 20% of U.S. cases.

Candida auris, in particular, has become one of the most concerning fungal threats in modern healthcare, as some strains have become resistant to all available antifungal treatments. "With ...

There have been 587 cases reported in the US, according to theCDC, most of them in New York, New Jersey and Illinois. A mysterious and dangerous fungal infection called Candida auris has emerged ...

A characteristic of Candida auris infection is that standard antifungal medications are sometimes completely ineffective or work poorly. Antifungal resistance is an ongoing issue that can develop ...

To prevent future antifungal resistance, scientists have developed tiny molecular drills. Candida auris is a relatively new addition to a family of fungi that can infect people. Most of these ...

More information: Rita R. Verma et al, Simulating a travel-related origin of Candida auris in New York–New Jersey, Microbiology Spectrum (2024). DOI: 10.1128/spectrum.02065-24 Provided by New ...